ArticleBioorganic & medicinal chemistry2016
Synthesis and investigation of novel benzimidazole derivatives as antifungal agents.
Article in Bioorganic & medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 135 citations in OpenAlex.
- Progress in Synthesis and Pharmacology of Telmisartan.Chemistry & biodiversity · 2026Review
- Synthesis, biological evaluation, and docking analysis of novel benzimidazole-triazole hybrids as potential anticancer agents.RSC advances · 2025Article
- New Therapeutic Options for Fusariosis: A Patent Review (2008-2023).Journal of fungi (Basel, Switzerland) · 2025Article
- Multifunctional Heterogeneous Cobalt Catalyst for the One-Pot Synthesis of Benzimidazoles by Reductive Coupling of Dinitroarenes with Aldehydes in Water.ChemSusChem · 2025Article
- Benzimidazole(s): synthons, bioactive lead structures, total synthesis, and the profiling of major bioactive categories.RSC advances · 2025Review
- Discovery of a novel benzimidazole conjugated quinazolinone derivative as a promising SARS-CoV-2 3CL protease inhibitor.RSC advances · 2024Article
- Article
- A Critical Review on Therapeutic Potential of Benzimidazole Derivatives: A Privileged Scaffold.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2024Review
- Benzimidazole as a Privileged Scaffold in Drug Design and Discovery.Current topics in medicinal chemistry · 2024Review
- Article
- Estragole Inhibits Growth and Aflatoxin Biosynthesis ofMicrobiology spectrum · 2023Article
- Building Up a Piperazine Ring from a Primary Amino Group via Catalytic Reductive Cyclization of Dioximes.International journal of molecular sciences · 2023Article
- Discovery and development of novel substituted monohydrazides as potent antifungal agents.RSC medicinal chemistry · 2023Article
- Benzimidazole Derivatives Suppress Fusarium Wilt Disease via Interaction withJournal of fungi (Basel, Switzerland) · 2023Article
- Novel tetrahydropyrimidinyl-substituted benzimidazoles and benzothiazoles: synthesis, antibacterial activity, DNA interactions and ADME profiling.RSC medicinal chemistry · 2022Article
- Synthesis, Antiproliferative Evaluation and QSAR Analysis of Novel Halogen- and Amidino-Substituted Benzothiazoles and Benzimidazoles.International journal of molecular sciences · 2022Article
- Selective Inhibition of the Periodontal PathogenJournal of medicinal chemistry · 2022Article
- Bio-priming with a consortium ofFrontiers in microbiology · 2022Article
- Nucleus-Independent Chemical Shift (NICS) as a Criterion for the Design of New Antifungal Benzofuranones.Molecules (Basel, Switzerland) · 2021Article
- Preparation of 1,2-substituted benzimidazolesRSC advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The rise and emergence of resistance to antifungal drugs by diverse pathogenic fungal strains have resulted in an increase in demand for new antifungal agents. Various heterocyclic scaffolds with different mechanisms of action against fungi have been investigated in the past. Herein, we report the synthesis and antifungal activities of 18 alkylated mono-, bis-, and trisbenzimidazole derivatives, their toxicities against mammalian cells, as well as their ability to induce reactive oxygen species (ROS) in yeast cells. Many of our bisbenzimidazole compounds exhibited moderate to excellent antifungal activities against all tested fungal strains, with MIC values ranging from 15.6 to 0.975μg/mL. The fungal activity profiles of our bisbenzimidazoles were found to be dependent on alkyl chain length. Our most potent compounds were found to display equal or superior antifungal activity when compared to the currently used agents amphotericin B, fluconazole, itraconazole, posaconazole, and voriconazole against many of the strains tested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.